in 12 patients ( 11 girls , 1 boy ) with central precocious puberty and 4 patients ( 3 girls , 1 boy ) with idiopathic short stature treated for 1 year with a gnrh superagonist , buserelin ( 0.3 mg intranasally , 4 times a day ) , a variable degree of inhibition of sex steroid secretion and pubertal development was observed .
C0023610
gnrh
C0006456
buserelin